Myelodysplastic syndromes

Active Research Protocols

  1. 00-H-0169 – A Phase II Study of Antithymocyte Globulin (ATG) and Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)
  2. 01-C-0125 – Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
  3. 01-H-0162 – Ex Vivo Selective Depletion of Alloreactive Donor T-Lymphocytes Using RFT5-SMPT-dgA, a Specific Anti-Interleukin-2 Receptor Immunotoxin: Reducing GVHD Risk Associated with HLA-Matched, Nonmyeloablative, Peripheral Blood Stem Cell Transplantation for Hemat
  4. 03-H-0192 – Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed by T Cell Add-Back for Hematological Malignancies ? Effect of Irradiated Donor Lymphocytes on Chimerism
  5. 04-C-0102 – Hematologic Malignancy Biology Study
  6. 04-H-0112 – Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed by T Cell Add-Back for Hematological Malignancies - Effect of Peritransplant Cyclosporine on Chimerism
  7. 04-H-0213 – Cytokine Gene Polymorphisms in Bone Marrow Failure
  8. 05-H-0206 – A Pilot Study of Alemtuzumab (Campath[R]) in Patients with Myelodysplastic Syndrome (MDS)
  9. 07-C-0195 – Phase II Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Treatment of Leukemias, Lymphomas, and Pre-malignant Blood Disorders
  10. 07-H-0136 – Selective Depletion of Alloreacting T Cells Using a Photodepletion Technique to Prevent GVHD after HLA-Matched Peripheral Blood Stem Cell Transplantation for Subjects with Hematologic Malignancies
  11. 07-H-0159 – Efficacy of WT1 and PRI Peptide Vaccination for Patients with Low Risk Myeloid Malignancies
  12. 07-H-0225 – A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients with RAEB-1 AND RAEB-2 Myelodysplastic Syndrome (MDS) and AML with Trisomy 8
  13. 08-H-0046 – Co-Infusion of Umbilical Cord Blood and Haploidentical CD34+ Cells Following Nonmyeloablative Conditioning as Treatment for Severe Aplastic Anemia and MDS Associated with Severe Neutropenia Refractory to Immunosuppressive Therapy
  14. 09-C-0096 – Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for Patients with GATA2 Mutations
  15. 09-H-0087 – Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation
  16. 09-H-0199 – A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R agonist), Eltrombopag, in Patients with Low to Int-2 Risk Myelodysplastic Syndrome (MDS)
  17. 10-H-0154 – Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused with a Reduced Dose of Non-Mobilized Donor T-Cells
  18. 11-C-0136 – Multi-Institutional Prospective Pilot Study of Lupron to Enhance Lymphocyte Immune Reconstitution Following Allogeneic Bone Marrow Transplantation in Post-Pubertal Children and Adults with Molecular Imaging Evaluation
  19. 12-H-0028 – Peripheral Blood Stem Cell Allotransplantation for Hematological Malignancies Using Ex Vivo CD3, CD19 Depletion and CD34 Selection
  20. 12-H-0146 – Clofarabine Followed by Lenalidomide for Treatment of High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
  21. 13-C-0132 – Allogeneic Hematopoietic Stem Cell Transplant for Patients with Mutations in GATA2 or the MonoMAC syndrome
  22. 13-H-0144 – Peripheral Blood Stem Cell Allotransplantation For Hematological Malignancies Using Ex Vivo CD34 Selection - a Platform For Adoptive Cellular Therapies
  23. 97-H-0099 – HLA-Matched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed by T Cell Add-Back for Hematological Malignancies
  24. 97-H-0202 – Low Intensity Preparative Regimen Followed by HLA-Matched, Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in Older Adults
  25. 99-H-0046 – Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed by T-Cell Add-Back for Hematological Malignancies - Role of Cyclosporine
  26. 99-H-0050 – Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in High Risk Patients and in Patients with Debilitating Hematologic Diseases
NOTE: PDF documents require the free
Adobe Reader.
This page was last updated: January 24, 2014